


## Cyclocreatine phosphate

Cat. No.:	HY-148150
CAS No.:	61839-19-8
Molecular Formula:	C <sub>5</sub> H <sub>10</sub> N <sub>3</sub> O <sub>5</sub> P
Molecular Weight:	223.12
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Cyclocreatine phosphate is an anti-tumor agent. Cyclocreatine phosphate is the proposed active form of cyclocreatine (CCr), a substrate analogue of creatine kinase. Cyclocreatine phosphate has anti-tumour activity and can be used for the research of cancer <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Cyclocreatine phosphate (CCr'P) (i.p.; 37.5 mg/mL; 0.2 mL, twice daily) has anti-tumor activity without any notable signs of toxicity in a mouse xenograft model for human prostate cancer<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Athymic (CD1-Nu/Nu) male mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>37.5 mg/mL</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneally , 0.2 mL, twice daily</td> </tr> <tr> <td>Result:</td> <td>Showed anti-tumor effect.</td> </tr> </table>	Animal Model:	Athymic (CD1-Nu/Nu) male mice <sup>[1]</sup>	Dosage:	37.5 mg/mL	Administration:	Intraperitoneally , 0.2 mL, twice daily	Result:	Showed anti-tumor effect.
Animal Model:	Athymic (CD1-Nu/Nu) male mice <sup>[1]</sup>								
Dosage:	37.5 mg/mL								
Administration:	Intraperitoneally , 0.2 mL, twice daily								
Result:	Showed anti-tumor effect.								

### REFERENCES

[1]. Rima Kaddurah-Daouk, et al. Creatine phosphate, creatine phosphate analogs, and uses therefor. Patent. WO1994016712A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA